AstraZeneca AZN announced positive top-line data from the phase III Bax24 study evaluating the safety, tolerability and ...

The new drug Baxdrostat lowers resistant hypertension in difficult-to-treat patients, showing promising results in a global clinical trial.

The U.S. Food and Drug Administration (FDA) approved sotatercept in March 2024 for treatment of pulmonary hypertension, ...

Baxdrostat improved ambulatory 24-hour average systolic blood pressure at 12 weeks compared with placebo in patients with ...

In top-line results, the phase III trial demonstrated a “highly clinically meaningful reduction” in 24-hour systolic BP.

Last year, Idorsia Pharma claimed FDA approval for Tryvio (aprocitentan) as the first endothelin receptor antagonist for ...

For the millions of people with hypertension, the condition feels like a ticking time bomb. Those who have it can struggle to keep it under control, even with medication. Now, D.C.-area doctors are ...

Resistant hypertension affects 1 in 10 with high BP, persisting despite multiple medications. Experts warn it needs early ...

AstraZeneca's experimental drug baxdrostat significantly lowered blood pressure in a 24-hour window during a late-stage trial ...

Prescribing the biologic drug sotatercept alongside standard treatment for the most severe form of pulmonary hypertension ...

The World Health Organization (WHO) today released its second Global hypertension report, showing that 1.4 billion people ...